BPC-157 vs KPV
BPC-157 completed a Phase 2 trial for ulcerative colitis, delivered by enema, and its results were never published. KPV has no published human trial of its own. The landmark KPV study put it in the drinking water of mice. A small uncontrolled knee-injection case series exists for BPC-157, but neither has controlled human evidence for the injectable uses promoted online.
- Healing and gut
- Both orally active
- No controlled injection evidence
Studied by mouth, sold in vials.
BPC-157 has an unpublished Phase 2 for ulcerative colitis and an uncontrolled knee-injection series. KPV has no published human trial. Neither has controlled evidence for the injectable uses promoted online.
| Attribute | BPC-157 | KPV |
|---|---|---|
| Length | 15 amino acids | 3 amino acids [1] |
| Comes from | A protein in gastric juice | The tail of alpha-MSH [1] |
| Human trials | Phase 1 and Phase 2, Phase 2 unpublished; one uncontrolled knee-injection series [2] | None published [3] |
| Route in those studies | Oral and enema in early development; knee injection in a small uncontrolled series [2] | Drinking water, in mice [4] |
| Route as sold | Injection | Injection |
| Orally active | Yes [2] | Yes, unusually for a peptide [4] |
Early oral and rectal studies do not establish efficacy; the separate knee-injection report is uncontrolled. See the route section.
BPC-157
A synthetic fragment of a protein found in human gastric juice. Its name stands for Body Protection Compound. In plain terms: a piece of something your stomach already makes, studied for gut healing and sold for tendons.
KPV
Lysine, proline and valine, the last three residues of alpha-MSH. It keeps the parent hormone's anti-inflammatory action and drops everything else it does. In plain terms: the part of the tanning hormone that calms inflammation, with the tanning removed.
KPV is positions 11 to 13 of alpha-MSH, the same hormone family as Melanotan I, Melanotan II and PT-141. It keeps the anti-inflammatory activity and loses the receptor binding that causes tanning, appetite change and the sexual effects.
Alpha-MSH is a thirteen amino acid hormone. Most of what it is known for, skin darkening and appetite suppression, comes from binding melanocortin receptors. That is the mechanism behind Melanotan I, Melanotan II and PT-141. [1]
The anti-inflammatory activity sits elsewhere, in the C-terminal tail, lysine-proline-valine, and it does not require the receptor at all. [1]
So KPV is a melanocortin fragment engineered, in effect, to stop being a melanocortin. It carries the part that calms inflammation and drops the part that darkens skin, changes appetite and drives sexual arousal. [1]
That makes it the opposite design choice from its relatives. Melanotan II was built to maximise receptor binding and produces tanning, nausea, appetite suppression and erections as a result. KPV was cut down to avoid all of it.
It also explains something about how KPV is sold. It appears in gut and skin products, never in tanning or libido products, despite sharing a parent hormone with compounds sold for exactly those things.
KPV enters cells through PepT1, a gut transporter that increases in inflamed tissue, then blocks NF-kB directly. BPC-157 works on blood vessel growth and growth factor signalling. The mechanisms are unrelated.
KPV gets inside the cell and blocks the switch. It is taken up by PepT1, a transporter that carries small peptides across the gut wall. Once inside, it inhibits NF-kB, the transcription factor that turns on most inflammatory genes. [4]
PepT1 is the reason KPV works by mouth, and oral activity is unusual for a peptide. Most peptides are digested before they reach circulation. KPV is small enough to use a transporter built for exactly that kind of molecule.
PepT1 also increases in inflamed intestinal tissue, so the transporter that carries KPV is more abundant precisely where the inflammation is. That is an elegant piece of biology and it is the strongest thing on KPV's side of this page. [4]
KPV also antagonises the IL-1 receptor, a second anti-inflammatory route independent of the melanocortin receptors. [1]
BPC-157 acts on tissue repair instead of the inflammatory switch. The proposed mechanisms centre on promoting new blood vessel growth, on the nitric oxide system, and on upregulating growth factor receptors in tendon and gut tissue. [2]
The two are complements, not alternatives. One suppresses an inflammatory signalling pathway and the other promotes repair and blood supply. They are sold together for that reason, and no published human trial has tested them together.
Early oral, rectal and limited injection evidence.
BPC-157 has early human development for ulcerative colitis and a small uncontrolled knee-injection series. KPV has no published human trial. Its landmark mouse study delivered the peptide in drinking water and reported neutrophil marker reductions of about 50 percent in one colitis model and 30 percent in another.
Work at the University of Texas establishes that the anti-inflammatory activity of alpha-MSH sits in its C-terminal tripeptide rather than in the receptor-binding region. Patents follow on lysine-proline-valine compositions for fever and inflammation. [1]
The Croatian pharmaceutical company Pliva develops BPC-157 under the designations PL-10, PLD-116 and ultimately PL 14736, aiming at inflammatory bowel disease. [2]
A Phase 1 study assesses safety, tolerability and pharmacokinetics in healthy male volunteers. It reports the compound safe. [2]
The Phase 2. Ruenzi and colleagues run a multicentre, randomised, double-blind, placebo-controlled study of PL 14736 enema in mild to moderate ulcerative colitis, presented at Digestive Disease Week. [2]
That design is rigorous by any standard, and the results were never published in a peer-reviewed journal. A conference abstract is all that exists. [2]
The landmark study. Dalmasso and colleagues publish in Gastroenterology. Mice with two different forms of induced colitis receive oral KPV in their drinking water. [4]
In the DSS model, myeloperoxidase activity, a marker of neutrophil infiltration, fell by roughly 50 percent. IL-6, IL-12, interferon gamma and IL-1 beta all dropped. Weight loss was attenuated by day 8.
In the TNBS model, myeloperoxidase fell by about 30 percent, with similar cytokine reductions.
The mechanism was confirmed by silencing PepT1 in cell lines, which abolished the effect. [4]
Xiao and colleagues publish in Molecular Therapy, showing that KPV delivered in targeted nanoparticles reduced colitis severity at doses far below those needed for free oral KPV. [4]
Lee and Padgett report a retrospective knee-injection series involving 17 patients. Sixteen were reached by telephone later. With no control group or objective functional measure, it cannot establish that the injections work. [2]
The FDA places KPV in a compounding category and states that it lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans. [3]
The FDA's advisory committee recommends BPC-157 for the compounding list. A recommendation is not approval, and rulemaking takes many months. [5]
Today BPC-157 has human data for a condition and a route almost nobody buys it for, and KPV has none at all.
Oral and rectal studies do not establish that the injectable products sold online work.
The oral route has the mechanistic and animal evidence for KPV; BPC-157 also has early oral and rectal development and a separate, uncontrolled knee-injection report.
BPC-157's early clinical development included oral and enema routes for ulcerative colitis. A separate uncontrolled knee-injection series involved 17 patients. [2] KPV's landmark study put the peptide in mouse drinking water. [4]
Both are sold in vials for injection.
For KPV the mismatch is sharper still, because oral activity is its distinguishing feature. It works by mouth because PepT1 carries it across the gut wall, and PepT1 is more abundant in inflamed intestinal tissue. [4] Inject it and you bypass the transporter that makes the mechanism work.
KPV has no human trial of any kind. As of 2026 no Phase 1 or Phase 2 study of KPV as a single ingredient appears on the clinical trials register, and the FDA has said in writing that it does not know whether KPV would cause harm in humans. [3]
BPC-157's human evidence has a hole in the middle of it. The Phase 2 in ulcerative colitis was multicentre, randomised, double-blind and placebo-controlled, which is the design everything else on this site is measured against. Its full results have never appeared in a peer-reviewed journal. [2]
A 2026 investigation by STAT News found that a 2025 review asserting the trial showed the drug safe and well tolerated offered no citation to a published paper and no data. [2]
So thirty years of animal work sits on one side, and on the other a completed Phase 2 whose findings nobody outside the sponsor has seen.
Everything that differs
| Attribute | BPC-157 | KPV |
|---|---|---|
| Also called | Body Protection Compound 157, PL 14736 | Lys-Pro-Val, alpha-MSH (11-13) |
| Length | 15 amino acids | 3 amino acids |
| Parent molecule | A protein in gastric juice | Alpha-MSH |
| Related to | Nothing else on this site | Melanotan I, Melanotan II, PT-141 |
| Mechanism | Angiogenesis, nitric oxide, growth factor receptors [2] | |
| Human trials | Phase 1, an unpublished Phase 2, and an uncontrolled knee-injection series [2] | None published [3] |
| Route in studies | Oral, enema, and knee injection in a separate case series [2] | Not applicable |
| Animal evidence | Extensive, tendon and gut | Two colitis models, oral [4] |
| Orally active | Yes | Yes, via PepT1 |
| Route as sold | Injection | Injection |
| FDA compounding status | Recommended July 2026, not approved [5] | Category listing, safety data cited as absent [3] |
| WADA 2026 | Prohibited, S0 [6] | Not named [6] |
BPC-157 has human trials and KPV has none. KPV is orally active through a gut transporter and BPC-157 is orally active too. Only one of them shares a parent hormone with three other compounds on this site.
both are peptide fragments of something larger · both are anti-inflammatory · both showed oral activity in the studies that exist · both are sold almost exclusively as injectables · both appear together in the KLOW blend
BPC-157
15 amino acids
None
Yes, ulcerative colitis
Oral and enema for early development; knee injection in an uncontrolled series
Repair and blood supply
Prohibited under S0
Recommended, not approved
KPV
3 amino acids
Melanocortin, via alpha-MSH
None
Oral, in mice
Blocks the inflammatory switch
Not named
Safety data cited as absent
KPV appears inside KLOW alongside BPC-157, GHK-Cu and TB-500, so four compounds share one vial. The reasoning is that one suppresses inflammation while the other promotes repair. No published human trial has tested any combination of them.
The two mechanisms genuinely do different jobs. KPV blocks NF-kB and quietens the inflammatory response. BPC-157 promotes blood vessel growth and tissue repair. Pairing them is not an unreasonable idea.
It has never been tested. No published human trial has examined BPC-157 with KPV, in any combination, at any dose.
The blend they most often appear in adds two more untested compounds. KLOW contains BPC-157, GHK-Cu, TB-500 and KPV. Four compounds, no trial of the blend, and TB-500's own evidence belongs to a protein six times its size.
Blends carry a practical problem beyond the evidence. When four compounds share a vial you cannot tell which one produced an effect or a problem, and you cannot adjust one without adjusting all four. That is one reason blends are rare in medicine, and it applies here regardless of whether the individual compounds work.
Nobody has published a human trial of KPV. BPC-157 has only an uncontrolled knee-injection series for musculoskeletal use, not a controlled efficacy trial. Nobody has tested the combination in a published human trial.
Nobody has given KPV to a person in a published trial. Not for gut inflammation, not for skin, not for anything. [3] Every claim made for it in humans is extrapolation from two mouse colitis models.
Nobody has published the BPC-157 Phase 2 results. The trial was completed. The design was multicentre, randomised, double-blind and placebo-controlled. Twenty years later the full findings have never appeared in a peer-reviewed journal, and a 2026 investigation found the safety claims made for it rest on a review citing no data. A separate uncontrolled knee-injection series cannot fill that gap. [2]
Nobody has established that either injectable product works for the uses it is sold for. BPC-157 has a small, uncontrolled knee-injection case series, alongside early oral and rectal clinical development for ulcerative colitis. [2] KPV's evidence here is oral, in mice. [4] Neither establishes efficacy for the injectable market.
Nobody knows whether injected KPV reaches its target at all. Its mechanism depends on PepT1, a gut transporter, so injecting it bypasses that route entirely. No study has examined whether the peptide still works arriving another way.
Nobody has tested the combination, either. BPC-157 with KPV is one of the most common pairings in this market, and it has never appeared in a published human trial.
BPC-157's human trials in ulcerative colitis reported it well tolerated. KPV has no human safety data at all, and the FDA has said in writing that it does not know whether KPV would cause harm in humans.
BPC-157
The only human safety data on this page.
KPV
This is not a clean safety record. It is no record.
No human trial of KPV as a single ingredient has been published [3]
No Phase 1 or Phase 2 study appears on the clinical trials register [3]
The FDA has stated it lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans [3]
Injected KPV bypasses PepT1, the transporter its mechanism depends on
What you are buying
Neither is an approved product anywhere.
The two halves of this register are not comparable, and that is the point. BPC-157 has human trials reporting it well tolerated, by routes almost nobody uses. KPV has nothing, and the regulator has said so in writing.
An absent safety record is not a good one. It means nobody has looked.
Both fall under section S0, which covers any substance not approved by any regulatory health authority for human use. BPC-157 is captured explicitly. KPV is not named, and since it is approved nowhere, the same clause almost certainly reaches it.
BPC-157 falls under section S0 of the 2026 Prohibited List, which covers any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. It is prohibited at all times. [6]
KPV is not named on the list, and it is almost certainly prohibited anyway. S0 covers any substance not approved by any governmental regulatory health authority for human therapeutic use. KPV is not approved anywhere, for anything, which is precisely the condition S0 describes. [6]
So the difference between the two compounds here is that BPC-157 is explicitly captured and KPV is captured by the same clause without being named. Neither is a safe choice for a tested athlete.
Anyone competing under a testing body should ask that body directly instead of reasoning from the list, particularly for a compound sold in blends where the other components are named.
Neither. BPC-157 was recommended for the compounding list in July 2026, a step that is not approval and does not permit compounding today. KPV's FDA listing cites the absence of human safety data.
Neither compound is approved for any indication, anywhere.
BPC-157 was recommended for the 503A bulk substances list by the FDA's advisory committee in July 2026. That recommendation is non-binding, the agency must accept it and run a formal rulemaking process that typically takes eight to twenty-four months, and BPC-157 cannot legally be compounded today. [5]
KPV's position is different and worse. Its FDA categorisation records that the agency lacks information about whether it would cause harm in humans. [3] A regulator has put on record that the basic safety question has not been asked.
One development is in motion and unresolved. In February 2026 the Secretary of Health and Human Services announced plans to reclassify roughly fourteen peptides, KPV among them, from Category 2 back to Category 1, which would permit licensed compounding pharmacies to prepare them on prescription. [3] That is an announcement rather than a completed rule, and it had not taken effect at the time of writing.
What that means practically. Both are sold as research chemicals. Neither can be obtained through a pharmacy today. The compounding recommendation for BPC-157 changes nothing about today's legal position and is frequently reported as though it does.
Questions people ask
Is KPV the same as BPC-157?
No, and they are unrelated. BPC-157 is a 15 amino acid fragment of a protein in gastric juice. KPV is three amino acids from the tail of alpha-MSH, the hormone behind tanning and appetite signalling.[1] Their mechanisms are different and they are sold together because of that.
Has KPV been tested in humans?
No. No human trial of KPV as a single ingredient has been published, and no Phase 1 or Phase 2 study appears on the clinical trials register as of 2026.[3] The FDA has stated in writing that it does not know whether KPV would cause harm in humans.
Can you take KPV orally?
That is how it was studied. The landmark trial gave KPV in the drinking water of mice, and it works by mouth because a gut transporter called PepT1 carries it across the intestinal wall.[4] Oral activity is unusual for a peptide and it is KPV's most distinctive property.
Should KPV be injected?
No study supports it. KPV's mechanism depends on PepT1, a transporter in the gut wall that becomes more abundant in inflamed tissue.[4] Injecting it bypasses that route, and nobody has tested whether the peptide still works when it arrives another way.
Is KPV related to Melanotan?
Yes, and it is the fragment that avoids being a melanocortin. KPV is positions 11 to 13 of alpha-MSH, the same parent hormone behind Melanotan I, Melanotan II and PT-141.[1] It keeps the anti-inflammatory activity and drops the receptor binding that causes tanning, appetite change and sexual arousal.
Did BPC-157 pass human trials?
It completed early studies, and the results of the important one were never published. A Phase 1 in healthy male volunteers reported it safe. A Phase 2 in mild to moderate ulcerative colitis was multicentre, randomised, double-blind and placebo-controlled, presented at a conference in 2005, and its full findings have never appeared in a peer-reviewed journal.[2] A separate registered oral Phase 1 has no posted results; its submitted results were recalled before review.
Can you take BPC-157 and KPV together?
Yes, people do, and no published human trial has tested the combination. They appear together in the KLOW blend alongside GHK-Cu and TB-500, which adds two more untested compounds to the same vial.
What is KPV used for?
Gut inflammation mainly, and inflammatory skin conditions. Both rest on two mouse colitis models and cell work.[4] It has no approved use anywhere and has never been tested in a person.
Does BPC-157 actually work?
Nobody outside its sponsor can check the Phase 2 results. The animal evidence spans more than thirty years and is extensive. The human evidence also includes a Phase 1 reporting it safe and a separate uncontrolled knee-injection series involving 17 patients, which cannot establish efficacy.[2] A 2026 investigation found the safety claims made for the Phase 2 cite no published data.
How much KPV should I take?
No human trial has established a dose, because no human trial exists.[3] The mouse study that defines the compound delivered KPV in drinking water rather than at a measured dose per animal.[4] Any protocol in circulation is community practice.
What are the side effects of KPV?
Unknown. No human trial of KPV has been published, and the FDA has stated in writing that it lacks information on whether KPV would cause harm in humans.[3] That is an absence of data rather than a clean record.
Is BPC-157 legal?
Not for sale as a drug or supplement in the United States. It cannot currently be legally compounded, though the FDA's advisory committee recommended it for the compounding list in July 2026.[5] That recommendation is non-binding and rulemaking takes many months.
Can KPV be used on skin?
It is sold for that, and the evidence is thinner than the gut evidence. KPV comes from alpha-MSH, which has documented anti-inflammatory activity in skin models, and KPV itself has cell and animal work behind it.[1] No human trial has tested it topically or otherwise.
Are they banned in sport?
Both, effectively. Section S0 prohibits any substance not approved by any governmental regulatory health authority for human therapeutic use.[6] BPC-157 is captured explicitly, and KPV is approved nowhere for anything, which is the exact condition S0 describes. Not being named is not clearance.
The published record
What Europe PMC and ClinicalTrials.gov hold for each, on the same rule.
BPC-157 has 240 records to KPV's 210. 24 original human studies against 32. BPC-157 has 4 registered trials to KPV's 0.
BPC-157: FDA: Use evaluated: ulcerative colitis · FDA: Nominated but withdrawn; previously category 2 (503A) · FDA: No USP or NF drug substance monograph; not a component of an approved drug · FDA: FDA staff proposed not adding to the 503A bulks list · WADA: Prohibited at all times, in and out of competition. S0 Non-approved substances: named as an example. Specified Substance. · FDA: Considered at the July 23, 2026 session
KPV: FDA: Uses evaluated: wound healing and inflammatory conditions · FDA: Nominated but withdrawn; previously category 2 · FDA: FDA staff proposed not adding to the 503A bulks list · FDA: Considered at the July 23, 2026 session
The published recordBPC-157
Papers and trials about BPC-157
56 papers tagged human · 24 not reviews or lab · 0 clinical trial publications
4 registered trials · none with posted results
Compare this against the whole library →
Use evaluated: ulcerative colitisRegulatorsCounted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
The published recordKPV
Papers and trials about KPV
50 papers tagged human · 32 not reviews or lab · 0 clinical trial publications
Compare this against the whole library →
Uses evaluated: wound healing and inflammatory conditionsRegulatorsCounted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
What this page is built on
- 01
KPV structure and origin. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, corresponding to positions 11 to 13: lysine, proline, valine. Alpha-MSH is a 13 amino acid hormone. The anti-inflammatory and antipyretic activity of alpha-MSH resides in this C-terminal sequence, not in the receptor-binding region; the core 4-10 sequence carries behavioural effects with little anti-inflammatory activity. KPV also exerts anti-inflammatory activity by antagonistically binding interleukin-1 receptor type I. US patents 5,028,592 (Lipton, 1991) and 5,157,023 (Lipton, 1992) cover antipyretic and anti-inflammatory Lys-Pro-Val compositions. Alpha-MSH is the same parent hormone behind Melanotan I, Melanotan II and PT-141, which act through melanocortin receptors that KPV does not engage.
- 02
BPC-157 clinical development. A 15 amino acid partial sequence of body protection compound isolated from human gastric juice, sequence GEPPPGKPADDAGLV, molecular weight 1419, described as stable in human gastric juice for more than 24 hours.
Developed by Pliva, a Croatian pharmaceutical company later acquired by Barr Pharmaceuticals and then Teva, under the designations PL-10, PLD-116 and PL 14736.
Phase 1: safety, tolerability and pharmacokinetics in healthy male volunteers, reported by Veljaca and colleagues. Reported safe; detailed results are scarce.
Phase 2: Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J, and the Ulcerative Colitis Study Group. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Presented at Digestive Disease Week, abstract in Gastroenterology 2005;128(4 Suppl 2):A584. The full results have never been published in a peer-reviewed journal.
On the safety claims: a STAT News investigation published 3 February 2026 reported that a 2025 review asserting this trial found the drug safe and well tolerated offered no citation to a published paper and no data.
A separate registered trial, NCT02637284, a Phase 1 of Bepecin (BPC 157) in healthy volunteers sponsored by PharmaCotherapia with single and multiple oral dosing, has no posted results. Submitted results were recalled before review, and the registry status is unknown.
Musculoskeletal use: Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine 2021;27(4):8-13. A retrospective series at one clinic: 17 patients received knee injections; 16 were reached by telephone later. It had no control group or objective functional outcome measurement. This is not a controlled trial of injectable efficacy.
Proposed mechanisms include promotion of angiogenesis, effects on the nitric oxide system, and upregulation of growth factor receptors.
- 03
KPV identity, trial status and regulatory position. Molecular formula C16H30N4O4, molecular weight 342.43, CAS 67727-97-3.
No human trial exists. A documented registry search for KPV as investigational product, verified 19 May 2026, found no Phase 1, Phase 2 or Phase 3 trial of the Lys-Pro-Val tripeptide for any indication. Substring false positives appear where "kpv" occurs in sponsor or institution names, and no primary KPV trial is registered. No peer-reviewed clinical trial of KPV for any indication has been published.
The FDA position. In its assessment for the bulk drug substances list, the agency stated it "lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans."
A live development. In February 2026 the Secretary of Health and Human Services announced plans to reclassify approximately fourteen peptides, including KPV, from Category 2 to Category 1, which would permit compounding on prescription. This was an announcement, not a completed rule, and had not taken effect at the time of writing.
- 04
Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. Mice with DSS-induced and TNBS-induced colitis received oral KPV in drinking water. In the DSS model, myeloperoxidase activity fell approximately 50 percent, with significant reductions in IL-6, IL-12, interferon gamma and IL-1 beta mRNA, and attenuated weight loss by day 8. In the TNBS model, myeloperoxidase fell approximately 30 percent with similar cytokine reductions. Mechanism confirmed by PepT1 silencing in cell lines, which abolished the effect. PepT1 is upregulated in inflamed intestinal tissue. And Xiao B, et al. Molecular Therapy. 2017: orally targeted KPV nanoparticles reduced colitis severity at doses far below free oral KPV.
- 05
US Food and Drug Administration, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. BPC-157 recommended for the 503A bulk drug substances list. Non-binding recommendation, not approval. Rulemaking typically takes 8 to 24 months. Compounding is not permitted today.
- 06
World Anti-Doping Agency, 2026 Prohibited List. Section S0 covers any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. BPC-157 is captured. KPV is not explicitly named, and because it is not approved by any regulatory authority anywhere, S0 applies to it on the plain reading of the clause.
- 07
Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. DOI 10.1016/j.talanta.2018.06.023.
- 08
NBC Washington. Lab finds problems in 30% of peptide vials tested. December 2024.